Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 4,729 Shares

Immunome, Inc. (NASDAQ:IMNM) CEO Clay Siegall acquired 4,729 shares of the stock in a transaction dated Tuesday, December 30th. The shares were bought at an average cost of $21.15 per share, with a total value of $100,018.35. Following the completion of the purchase, the chief executive officer directly owned 665,254 shares in the company, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Immunome Stock Performance

Shares of IMNM traded down $0.42 during trading hours on Tuesday, hitting $21.18. The stock had a trading volume of 1,086,787 shares, compared to its average volume of 1,282,883. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $25.30. The firm has a market cap of $1.94 billion, a P/E ratio of -7.18 and a beta of 2.17. The company’s fifty day simple moving average is $18.45 and its 200 day simple moving average is $13.26.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, sell-side analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on IMNM. Guggenheim raised their price target on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Truist Financial began coverage on shares of Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $21.00 target price on shares of Immunome in a research note on Friday, November 7th. Craig Hallum began coverage on shares of Immunome in a report on Friday, September 5th. They set a “buy” rating and a $26.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.09.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Redmile Group LLC boosted its holdings in Immunome by 11.0% in the first quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock valued at $36,081,000 after purchasing an additional 533,161 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Immunome by 8.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock valued at $57,304,000 after purchasing an additional 368,674 shares in the last quarter. EcoR1 Capital LLC boosted its stake in shares of Immunome by 5.2% during the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock valued at $27,454,000 after buying an additional 200,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Immunome by 6.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock valued at $17,305,000 after buying an additional 117,523 shares during the last quarter. Finally, Woodline Partners LP grew its position in shares of Immunome by 69.0% during the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock worth $11,157,000 after buying an additional 676,804 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.